Our bold vision is shared by a group of global investors and professionals with years of experience in bringing new medical devices to market.
Funding Snapshot
After initial funding from Sambatech Angel Investors, we raised $24M in Series A funding to advance our robotic platform for open surgery. The syndicate was led by Andera Partners with Panakès Partners, Fountain Healthcare and returning seed investor, Sambatech.
In 2022, we raised $75M in Series B funding to accelerate clinical trials and global commercialization. The round was led by Deerfield Management and RA Capital, with additional funding by existing investors and BioStar Capital. A Series B extension raised an additional $12M led by Wellington Partners and included BioStar Capital as an existing investor.
In February 2024, we raised an additional $110M in Series C equity financing, increasing the total investment to date in MMI to approximately $220M. The $110M round was led by a new investor, Fidelity Management & Research Company, with additional funding from existing investors. The Series C funds will support the commercialization of the Symani® Surgical System in large, high-growth markets, as well as continued investment in studies that generate clinical evidence and enable indication expansion.
Backed by Leading-Edge Partners
MMI
5022 Gate Parkway,
Building 500,
Jacksonville, FL 32256
5022 Gate Parkway,
Building 500,
Jacksonville, FL 32256
Product Information: connect@mmimicro.com
Symani Support: techsupport@mmimicro.com
The Symani Surgical System is authorized for use in the U.S. by the FDA and is a CE marked medical device. Clinical indications vary by geography. Refer to global indications for more information. © 2024 Medical Microinstruments, Inc. All Rights Reserved.